How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes.

abstract：INTRODUCTION:Guidelines provide recommendations on the management of multiple myeloma (MM), but there are no standard algorithms for the choice and sequencing of treatments. As a result, there is widespread variation in the interpretation and implementation of these guidelines. Areas covered: This review will cover: th...

journal_title：Expert review of hematology

authors： Cavo M,Terpos E,Bargay J,Einsele H,Cavet J,Greil R,de Wit E

更新日期：2018-03-01 00:00:00

abstract：:Introduction: Myelodysplastic Syndrome (MDS) represents a group of cancers characterized by abnormal blood cell formation and maturation, leading to various degrees of cytopenias and potential transformation to acute myeloid leukemia. Deletion of the long arm of chromosome 5 (del(5q)) is the most common clonal chromos...

journal_title：Expert review of hematology

authors： Gorshein E,Weber UM,Gore S

更新日期：2020-03-01 00:00:00

abstract：INTRODUCTION:Iliopsoas muscle hemorrhage in patients with hemophilia is a serious complication with relevant related morbidity. AREAS COVERED:A Cochrane Library and PubMed (MEDLINE) search of studies related to iliopsoas hematomas in hemophilia was analyzed. Pain in the hip joint area and femoral nerve involvement in ...

journal_title：Expert review of hematology

authors： Rodriguez-Merchan EC,De la Corte-Rodriguez H

更新日期：2020-08-01 00:00:00

abstract：INTRODUCTION:The most common forms of hematological malignancies that occur in female reproductive years are lymphoma and leukemia. Areas covered: Several aggressive gonadotoxic regimens such as alkylating chemotherapy and total body irradiation are used frequently in treatment of lymphoma and leukemia leading to subse...

journal_title：Expert review of hematology

authors： Salama M,Isachenko V,Isachenko E,Rahimi G,Mallmann P

更新日期：2017-11-01 00:00:00

abstract：:Primary mediastinal large B-cell lymphoma (PMBCL) is a unique B-cell lymphoma variant that arises from a putative thymic medulla B cell. It constitutes 2-4% of non-Hodgkin lymphomas and occurs most frequently in young females. PMBCL is characterized by a diffuse proliferation of medium-to-large B cells associated with...

journal_title：Expert review of hematology

authors： Martelli M,Di Rocco A,Russo E,Perrone S,Foà R

更新日期：2015-04-01 00:00:00

abstract：:Early evidence has already shown that activated platelets play a role in the intrinsic pathway of coagulation, but the mechanism remained unclear. The finding that the dense granules of platelets contain polyphosphate (polyP), which has procoagulant effects, resolved this missing link between activated platelets and c...

journal_title：Expert review of hematology

authors： van der Meijden PE,Heemskerk JW

更新日期：2010-06-01 00:00:00

abstract：:The fms-like tyrosine kinase 3 (FLT3) plays an important role in both normal and malignant hematopoiesis. Activating mutations in the FLT3 receptor can be detected in approximately 30% of acute myeloid leukemias (AMLs) and are associated with a distinctly poor clinical outcome for patients. There are now several class...

journal_title：Expert review of hematology

authors： el-Shami K,Stone RM,Smith BD

更新日期：2008-12-01 00:00:00

abstract：:Venous thromboembolism is a common cause of morbidity and mortality among patients undergoing elective orthopedic surgery. Due to the high incidence of venous thromboembolism in this setting, perioperative anticoagulation is the recommended approach for thromboprophylaxis. Low molecular weight heparin (LMWH), fondapar...

journal_title：Expert review of hematology

authors： Rachidi S,Aldin ES,Greenberg C,Sachs B,Streiff M,Zeidan AM

更新日期：2013-12-01 00:00:00

abstract：INTRODUCTION:Catastrophic antiphospholipid syndrome (CAPS) is a rare, life-threatening disease. In 1992, Asherson defined it as a widespread coagulopathy related to the antiphospholipid antibodies (aPL). CAPS requires rapid diagnosis and prompt initiation of treatment. Areas covered: This paper discusses all aspects of...

journal_title：Expert review of hematology

authors： Carmi O,Berla M,Shoenfeld Y,Levy Y

更新日期：2017-04-01 00:00:00

abstract：:Despite significant improvements in treatment modalities over the 10 years, the clinical course of patients with follicular lymphoma (FL) remains heterogeneous. Thus, prognostic indexes are still required to direct treatment choices and for the design of clinical trials. Investigators have conducted a variety of studi...

journal_title：Expert review of hematology

authors： Luminari S,Cox MC,Montanini A,Federico M

更新日期：2009-10-01 00:00:00

abstract：INTRODUCTION:Recent advances and drug approvals in the last decade have substantially changed the landscape of relapsed and refractory multiple myeloma (RRMM), which not only improved outcomes for patients but also increased complexity of treatment decisions. The approvals are based on randomized studies of novel agent...

journal_title：Expert review of hematology

authors： Sanchez L,Barley K,Richter J,Franz J,Cho HJ,Jagannath S,Madduri D,Parekh S,Richard S,Chari A

更新日期：2020-09-01 00:00:00

abstract：:Anti-CD20 monoclonal antibodies (mAbs), rituximab, ofatumumab and obinutuzumab, have a significant impact in the treatment of chronic lymphocytic leukemia (CLL), particularly in combination with chemotherapy. Over the last few years, several new mAbs have been developed and investigated in CLL. The most promising newe...

journal_title：Expert review of hematology

authors： Robak T

更新日期：2014-12-01 00:00:00

abstract：:Many patients with acute myeloid leukemia will eventually develop refractory or relapsed disease. In the absence of standard therapy for this population, there is currently an urgent unmet need for novel therapeutic agents. Targeted therapy with small molecule inhibitors represents a new therapeutic intervention that ...

journal_title：Expert review of hematology

authors： Al-Hussaini M,DiPersio JF

更新日期：2014-08-01 00:00:00

abstract：INTRODUCTION:Pulmonary hypertension (PH) develops in a significant number of patients with sickle cell disease (SCD), resulting in increased morbidity and mortality. This review focuses on PH pathophysiology, risk stratification, and new recommendations for screening and treatment for patients with SCD. Areas covered: ...

journal_title：Expert review of hematology

authors： Shilo NR,Morris CR

更新日期：2017-10-01 00:00:00

abstract：INTRODUCTION:Purine analogs made dramatic improvements for patients with hairy cell leukemia (HCL), but patients often relapse, require multiple treatments, and may become refractory. Major developments in treatment of relapsed/refractory HCL occurred with discovery of disease biology. New agents increase the complexit...

journal_title：Expert review of hematology

authors： Chihara D,Kreitman RJ

更新日期：2020-10-01 00:00:00

abstract：:The introduction of bortezomib, a first-generation proteasome inhibitor, changed the standard-of-care for newly diagnosed and relapsed multiple myeloma patients. The next generation of proteasome inhibitors, such as carfilzomib, provides a novel pharmacokinetic and pharmacodynamic profile. In vitro data suggest a more...

journal_title：Expert review of hematology

authors： Khan RZ,Badros A

更新日期：2012-08-01 00:00:00

abstract：INTRODUCTION:Hodgkin's lymphoma (HL) is largely a curable disease with excellent prognosis. The standard of care in patients with relapsed disease has been to try salvage chemotherapy followed by an autologous stem cell transplantation (ASCT). Managing the patients who relapse after ASCT, is challenging. With the appro...

journal_title：Expert review of hematology

authors： Kallam A,Armitage JO

更新日期：2018-04-01 00:00:00

abstract：INTRODUCTION:Waldenström's macroglobulinemia (WM) is a rare, incurable B-cell lymphoma, with a median survival of 5-10 years in symptomatic patients. There is no consensus on the standard of care and several agents are currently used in these patients. Areas covered: In this article, we will review the use of standard ...

journal_title：Expert review of hematology

authors： Benevolo G,Nicolosi M,Santambrogio E,Vitolo U

更新日期：2017-07-01 00:00:00

abstract：INTRODUCTION:Haploidentical stem cell transplantation (Haplo-SCT) is currently a suitable alternative worldwide for patients with hematological diseases, who lack human leukocyte antigen (HLA)-matched siblings or unrelated donors. Areas covered: This review summarizes the advancements in Haplo-SCT in recent years, prim...

journal_title：Expert review of hematology

authors： Sun YQ,Chang YJ,Huang XJ

更新日期：2018-04-01 00:00:00

abstract：:Internal tandem duplication mutations of FMS-like tyrosine kinase-3 (FLT3) have been associated with poor outcomes in acute myelogenous leukemia. Over the course of the last several years, multiple agents have been developed and studied as potential inhibitors of FLT3 with the hope of providing clinical benefit for th...

journal_title：Expert review of hematology

authors： Fathi AT,Levis M

更新日期：2009-02-01 00:00:00

abstract：:Major advances have significantly improved the outcome of mantle cell lymphoma (MCL). Incorporation of rituximab to CHOP regimen, the adoption of high dose cytarabine with frontline autologous stem cell transplantation in young patients, maintenance rituximab or bortezomib based chemotherapy in elderly patients, impro...

journal_title：Expert review of hematology

authors： El Halabi L,Ghez D,Ribrag V

更新日期：2016-03-01 00:00:00

abstract：:Here we review the recent literature on Hemophilia gene transfer/therapy. Gene therapy is one of several new technologies being developed as a treatment for bleeding disorders. We will discuss current and pending clinical efforts and attempt to relate how the field is trending. In doing so, we will focus on the use of...

journal_title：Expert review of hematology

authors： Ward P,Walsh CE

更新日期：2016-07-01 00:00:00

abstract：:Introduction: Oral anticoagulants (OACs) are established treatments to reduce thromboembolic risk in patients with atrial fibrillation (AF). Due to their mechanisms of action, they are associated with increased bleeding risk. Evaluation with bleeding risk scores may be useful to identify patients at high risk. However...

journal_title：Expert review of hematology

authors： Kozieł M,Ding WY,Kalarus Z,Lip GYH

更新日期：2019-10-01 00:00:00

abstract：INTRODUCTION:In the last decade, the availability of new drugs for the treatment of Multiple Myeloma (MM) significantly improved patients' outcomes, but also raised attention towards a new spectrum of adverse events. Recently, four novel agents with different mechanisms of action (carfilzomib, elotuzumab, daratumumab a...

journal_title：Expert review of hematology

authors： Brioli A,Mügge LO,Hochhaus A,Von Lilienfeld-Toal M

更新日期：2017-03-01 00:00:00

abstract：:Thromboembolic diseases require anticoagulation for their prevention and treatment. New oral anticoagulants, specifically direct factor Xa and thrombin inhibitors, were developed to overcome the limitations of conventional anticoagulants. Their benefit has been demonstrated using fixed doses without laboratory-guided ...

journal_title：Expert review of hematology

authors： Harenberg J,Marx S,Erdle S,Krämer R

更新日期：2012-02-01 00:00:00

abstract：:Ofatumumab is a humanized second-generation monoclonal antibody with the affinity to a transmembrane protein CD20. In in vitro studies, it exhibits higher efficacy towards chronic lymphocytic leukemia (CLL) cells compared to rituximab, and it can be explained by the fact that its epitope on the target CD20 protein is ...

journal_title：Expert review of hematology

authors： Grosicki S

更新日期：2015-06-01 00:00:00

abstract：:Recent studies have identified recurrent mutations in genes that encode proteins crucial in the epigenetic regulation of gene transcription in hematologic malignancies. Somatic mutations in epigenetic modifiers, including IDH1, IDH2, TET2, DNAMT3A, ASXL1, MLL and EZH2 are enriched in patients with acute myeloid leukem...

journal_title：Expert review of hematology

authors： Hou HA,Tien HF

更新日期：2016-05-01 00:00:00

abstract：:Myeloid sarcoma (MS) is an extramedullary myeloid neoplasm characterized by proliferation of myeloblasts which can occur in any organ or site. Bronchial and pulmonary involvement, however, is uncommon. We describe a case of bronchial MS in an 81-year-old female with a history of high-grade myelodysplastic syndrome; sh...

journal_title：Expert review of hematology

authors： Vennepureddy A,Valecha G,Murukutla S,Hussein S,Terjanian T

更新日期：2015-08-01 00:00:00

abstract：BACKGROUND:Hb H disease is an alpha-thalassemia (α-thal) syndrome characterized by chronic hemolytic anemia that occurs when three of total four α-globin genes lost their function due to completely deletions or different kind of mutations. OBJECTIVE:We here described 66 patients who have been diagnosed for Hb H diseas...

journal_title：Expert review of hematology

authors： Farashi S,Bayat N,Vakili S,Faramarzi Garous N,Ashki M,Imanian H,Najmabadi H,Azarkeivan A

更新日期：2016-01-01 00:00:00

abstract：:β-thalassemias are caused by nearly 300 mutations of the β-globin gene, leading to a low or absent production of adult hemoglobin (HbA). Two major therapeutic approaches have recently been proposed: gene therapy and induction of fetal hemoglobin (HbF) with the objective of achieving clinically relevant levels of Hbs. ...

journal_title：Expert review of hematology

authors： Breda L,Rivella S,Zuccato C,Gambari R

更新日期：2013-06-01 00:00:00